| Challenges in the development of magnetic particles for therapeutic applications. | |
| | |
MedLine Citation:
|
PMID: 18608583 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Certain iron-based particle formulations have useful magnetic properties that, when combined with low toxicity and desirable pharmacokinetics, encourage their development for therapeutic applications. This mini-review begins with background information on magnetic particle use as MRI contrast agents and the influence of material size on pharmacokinetics and tissue penetration. Therapeutic investigations, including (1) the loading of bioactive materials, (2) the use of stationary, high-gradient (HG) magnetic fields to concentrate magnetic particles in tissues or to separate material bound to the particles from the body, and (3) the application of high power alternating magnetic fields (AMF) to generate heat in magnetic particles for hyperthermic therapeutic applications are then surveyed. Attention is directed mainly to cancer treatment, as selective distribution to tumors is well-suited to particulate approaches and has been a focus of most development efforts. While magnetic particles have been explored for several decades, their use in therapeutic products remains minimal; a discussion of future directions and potential ways to better leverage magnetic properties and to integrate their use into therapeutic regimens is discussed. |
| | |
Authors:
|
Stephen E Barry |
Related Documents
:
|
11777223 - Prosthetic heart valves and annuloplasty rings: assessment of magnetic field interactio... 7610123 - Positron emission tomography within a magnetic field using photomultiplier tubes and li... 11210093 - Technetium-99m mibi single photon emission computed tomography as an indicator of progn... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review |
Journal Detail:
|
Title: International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group Volume: 24 ISSN: 1464-5157 ISO Abbreviation: Int J Hyperthermia Publication Date: 2008 Sep |
Date Detail:
|
Created Date: 2008-10-16 Completed Date: 2009-01-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8508395 Medline TA: Int J Hyperthermia Country: England |
Other Details:
|
Languages: eng Pagination: 451-66 Citation Subset: IM |
Affiliation:
|
Alnis BioSciences, Inc., Research Triangle Park, NC 27709, USA. sbarry@oncologic.net |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Contrast Media / administration & dosage, pharmacokinetics Drug Delivery Systems* Electromagnetic Fields Ferric Compounds / administration & dosage, chemistry, pharmacokinetics Hot Temperature Humans Magnetic Resonance Imaging Magnetics* Nanoparticles* Neoplasms / therapy Particle Size |
| Grant Support | |
ID/Acronym/Agency:
|
HHSN261200411004C//PHS HHS |
| Chemical | |
Reg. No./Substance:
|
0/Contrast Media; 0/Ferric Compounds; 1309-37-1/ferric oxide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous m...
Next Document: RF ablation with adjuvant therapy: comparison of external beam radiation and liposomal doxorubicin o...